Status:
COMPLETED
A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone
Lead Sponsor:
Takeda
Conditions:
Relapsed and/or Refractory Multiple Myeloma
Eligibility:
All Genders
20+ years
Brief Summary
The purpose of this study is to investigate the real world effectiveness and safety of ixazomib in combination with lenalidomide and dexamethasone (IRd) in patients with relapsed and/or refractory mul...
Detailed Description
The drug being tested in this study is called Ixazomib. Ixazomib is being tested to treat people who have relapsed and/or refractory multiple myeloma (RRMM) under the conditions of standard medical ca...
Eligibility Criteria
Inclusion
- Men and women aged 20 years or older at the time of enrollment
- Patients with RRMM
- Participants who are scheduled to start IRd therapy
- Participants who can provide written informed consent of their own free will before the start of study treatment
- Participants who are judged by the principal investigator or investigator(s) to have the faculty to understand and comply with the requirements of the study
Exclusion
- Female Participants who are nursing or pregnant
- Participants who have been treated with ixazomib
- Participants with hypersensitivity to any of the components of IRd therapy, their analogs or excipients
- Participants with another active malignancy, i.e. synchronous active malignancy or previous malignancy with a disease-free period of less than 5 years, except for participants with carcinoma in situ (intraepithelial carcinoma) or intramucosal carcinoma judged to be cured by topical treatment
- Participants who are not registered with, or comply with, the guidelines of the lenalidomide management program
- Participants who, in the judgement of the principal investigator or investigator(s), are considered to be unsuitable for enrolment into the study
Key Trial Info
Start Date :
April 2 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 11 2021
Estimated Enrollment :
295 Patients enrolled
Trial Details
Trial ID
NCT03433001
Start Date
April 2 2018
End Date
June 11 2021
Last Update
December 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Takeda Selected Site
Tokyo, Japan